文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

血管加压素及其类似物在休克状态中的应用:综述

Vasopressin and its analogues in shock states: a review.
PubMed 文献 · Ann Intensive Care · 2020-01-22
一句话结论血管加压素可减少脓毒症休克及心脏术后血管麻痹性休克患者的去甲肾上腺素用量,但未报告改善生存,且缺血事件等副作用常见。

本文为叙述性综述,总结血管加压素及其类似物在脓毒症休克和心脏术后血管麻痹性休克中的依据、获益与风险。精氨酸血管加压素通过V1a受体收缩血管,但因非选择性受体亲和力也激活V2、V1b及催产素受体,可能引起抗利尿、促凝(von Willebrand因子释放和血小板活化)等不良反应。脓毒症休克时血浆血管加压素水平低于预期,且对升压效应存在超敏反应。特利加压素和selepressin为对V1受体亲和力更高的合成类似物,潜在副作用更少。明确的是血管加压素给药可减少去甲肾上腺素需求,但迄今未报告生存改善,副作用频繁,尤其是缺血事件。

要点

  • 脓毒症休克患者血浆血管加压素水平低于预期,且对升压效应存在超敏反应。
  • 血管加压素给药可减少去甲肾上腺素需求,但迄今未报告生存改善。
  • 血管加压素副作用频繁,尤其是缺血事件。
  • 特利加压素和selepressin对V1受体亲和力更高,潜在副作用更少。
  • 血管加压素因非选择性受体亲和力可激活V2、V1b及催产素受体,可能引起抗利尿和促凝等不良效应。

适用人群与场景

  • 脓毒症休克患者。
  • 心脏手术后血管麻痹性休克患者。

研究设计与关键结果

  • 叙述性综述,总结血管加压素及其类似物在脓毒症休克和心脏术后血管麻痹性休克中的依据、获益与风险。
  • 脓毒症休克时血浆血管加压素水平低于预期,且对升压效应存在超敏反应。
  • 血管加压素给药可减少去甲肾上腺素需求,但迄今未报告生存改善,副作用频繁,尤其是缺血事件。
  • 特利加压素和selepressin为对V1受体亲和力更高的合成类似物,潜在副作用更少。

证据类型、等级与局限

  • 证据类型:叙述性综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Activation of arginine-vasopressin is one of the hormonal responses to face vasodilation-related hypotension. Released from the post-pituitary gland, vasopressin induces vasoconstriction through the activation of V1a receptors located on vascular smooth muscle cells. Due to its non-selective receptor affinity arginine-vasopressin also activates V2 (located on renal tubular cells of collecting ducts) and V1b (located in the anterior pituitary and in the pancreas) receptors, thereby potentially promoting undesired side effects such as anti-diuresis, procoagulant properties due to release of the von Willebrand's factor and platelet activation. Finally, it also cross-activates oxytocin receptors. During septic shock, vasopressin plasma levels were reported to be lower than expected, and a hypersensitivity to its vasopressor effect is reported in such situation. Terlipressin and selepressin are synthetic vasopressin analogues with a higher affinity for the V1 receptor, and, hence, potentially less side effects. In this narrative review, we present the current knowledge of the rationale, benefits and risks of vasopressin use in the setting of septic shock and vasoplegic shock following cardiac surgery. Clearly, vasopressin administration allows reducing norepinephrine requirements, but so far, no improvement of survival was reported and side effects are frequent, particularly ischaemic events. Finally, we will discuss the current indications for vasopressin and its agonists in the setting of septic shock, and the remaining unresolved questions.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Demiselle J, Fage N, Radermacher P, et al. Vasopressin and its analogues in shock states: a review. Ann Intensive Care. 2020. PMID: 31970567. doi:10.1186/s13613-020-0628-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。